Compare fureasu Co., Ltd. with Similar Stocks
Dashboard
1
With a growth in Operating Profit of 35.96%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- NET PROFIT(HY) Higher at JPY 232.16 MM
- ROCE(HY) Highest at 27.3%
2
With ROCE of 6.57%, it has a very attractive valuation with a 0.95 Enterprise value to Capital Employed
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,037 Million (Micro Cap)
6.00
NA
0.00%
-0.03
22.52%
0.93
Revenue and Profits:
Net Sales:
1,474 Million
(Quarterly Results - Mar 2026)
Net Profit:
120 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.25%
0%
-0.25%
6 Months
-2.05%
0%
-2.05%
1 Year
-6.46%
0%
-6.46%
2 Years
-42.89%
0%
-42.89%
3 Years
-20.1%
0%
-20.1%
4 Years
-4.81%
0%
-4.81%
5 Years
-25.87%
0%
-25.87%
fureasu Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.32%
EBIT Growth (5y)
35.17%
EBIT to Interest (avg)
6.81
Debt to EBITDA (avg)
3.76
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
1.90
Tax Ratio
20.85%
Dividend Payout Ratio
5.39%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.27%
ROE (avg)
3.35%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.94
EV to EBIT
14.49
EV to EBITDA
6.19
EV to Capital Employed
0.95
EV to Sales
0.28
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
6.57%
ROE (Latest)
16.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,474.50
1,569.90
-6.08%
Operating Profit (PBDIT) excl Other Income
201.20
107.10
87.86%
Interest
11.30
10.90
3.67%
Exceptional Items
11.20
-8.30
234.94%
Consolidate Net Profit
119.90
115.50
3.81%
Operating Profit Margin (Excl OI)
73.30%
68.20%
0.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -6.08% vs -28.62% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 3.81% vs -66.45% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
7,637.50
7,582.60
0.72%
Operating Profit (PBDIT) excl Other Income
482.70
134.60
258.62%
Interest
100.10
102.30
-2.15%
Exceptional Items
23.00
-1.10
2,190.91%
Consolidate Net Profit
508.90
-244.50
308.14%
Operating Profit Margin (Excl OI)
38.40%
-13.90%
5.23%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 0.72% vs 32.80% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 308.14% vs -519.38% in Mar 2025
About fureasu Co., Ltd. 
fureasu Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






